MRI contrast agent (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "MRI contrast agent" in English language version.
refsWebsite
Global rank
English rank
11th place
8th place
5th place
5th place
1st place
1st place
low place
low place
low place
low place
low place
low place
9,562nd place
low place
low place
low place
low place
low place
518th place
331st place
low place
low place
low place
low place
18th place
17th place
6th place
6th place
3rd place
3rd place
acadpharm.org
- Profil toxicologique des chélates de gadolinium pour l'IRM : où en est-on ? [Toxicological profile of gadolinium chelates for MRI: where do we stand?] (PDF). acadpharm.org (Report) (in French). Academie de pharmacie. 2014.
amagpharma.com
- "Feridex". Amagpharma.com. Archived from the original on 15 June 2012. Retrieved 20 June 2012.
archive.org
- Lee, Joseph K.T. (2006). Computed Body Tomography with MRI Correlation. Lippincott Williams & Wilkins. p. 87. ISBN 978-0-7817-4526-0 – via Internet Archive. (Lee, Joseph K. T. (23 August 2023). equivalent link. Lippincott Williams & Wilkins. ISBN 9780781745260 – via Google Books.
books.google.com
- Lee, Joseph K.T. (2006). Computed Body Tomography with MRI Correlation. Lippincott Williams & Wilkins. p. 87. ISBN 978-0-7817-4526-0 – via Internet Archive. (Lee, Joseph K. T. (23 August 2023). equivalent link. Lippincott Williams & Wilkins. ISBN 9780781745260 – via Google Books.
c2i2.org
- "Gadolinium and NSF: What is fact and what is theory?". c2i2.org. 2008. volume vi, issue 2. Retrieved 23 July 2023.[dead link]
centerwatch.com
- "Newly approved drug therapies (105) GastroMARK (Advanced Magnetics)". CenterWatch. Archived from the original on 29 December 2011. Retrieved 20 June 2012.
doi.org
- Geraldes, Carlos F.G.C.; Laurent, Sophie (2009). "Classification and basic properties of contrast agents for magnetic resonance imaging". Contrast Media & Molecular Imaging. 4 (1): 1–23. doi:10.1002/cmmi.265. PMID 19156706.
- Tircsó, Gyulia; Molńar, Enricő; Csupász, Tibor; Garda, Zoltan; Botár, Richárd; Kálmán, Ferenc K.; Kovács, Zoltan; Brücher, Ernő; Tóth, Imre (2021). "Chapter 2. Gadolinium(III)-based contrast agents for magnetic resonance imaging: A re-appraisal". Metal Ions in Bio-Imaging Techniques. Springer. pp. 39–70. doi:10.1515/9783110685701-008. S2CID 233702931.
- McLeod, Shauanna M.; Mead, Thomas J. (2021). "Chapter 12. Magnetic resonance theranostics: An overview of gadolinium(II)-based strategies and magnetic particle imaging". Metal Ions in Bio-Imaging Techniques. Springer. pp. 347–370. doi:10.1515/9783110685701-018. S2CID 233710460.
- Lentschig, M.G.; Reimer, P.; Rausch-Lentschig, U.L.; Allkemper, T.; Oelerich, M.; Laub, G. (1998). "Breath-hold gadolinium-enhanced MR angiography of the major vessels at 1.0 T: Dose-response findings and angiographic correlation". Radiology. 208 (2): 353–357. doi:10.1148/radiology.208.2.9680558. PMID 9680558.
- Lee MJ, Kim MJ, Yoon CS, Song SY, Park K, Kim WS (2011). "The T2-shortening effect of gadolinium and the optimal conditions for maximizing the CNR for evaluating the biliary system: a phantom study". Korean Journal of Radiology. 12 (3): 358–364. doi:10.3348/kjr.2011.12.3.358. PMC 3088853. PMID 21603295.
- Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK (November 2016). "MRI contrast agents: Classification and application (Review)". International Journal of Molecular Medicine. 38 (5): 1319–1326. doi:10.3892/ijmm.2016.2744. PMID 27666161.
- Bagnato F, Gauthier SA, Laule C, Moore G, Bove R, Cai Z, et al. (May 2020). "Imaging mechanisms of disease progression in multiple sclerosis: Beyond brain atrophy". Journal of Neuroimaging. 30 (3): 251–266. doi:10.1111/jon.12700. PMID 32418324. S2CID 218677556.
- Kanal, Emanuel (December 2016). "Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience". Magnetic Resonance Imaging. 34 (10): 1341–1345. doi:10.1016/j.mri.2016.08.017. ISSN 1873-5894. PMID 27608608.
- McDonald, Robert J.; Levine, Deborah; Weinreb, Jeffrey; Kanal, Emanuel; Davenport, Matthew S.; Ellis, James H.; Jacobs, Paula M.; Lenkinski, Robert E.; Maravilla, Kenneth R.; Prince, Martin R.; Rowley, Howard A. (November 2018). "Gadolinium retention: A research roadmap from the 2018 NIH / ACR / RSNA workshop on gadolinium chelates". Radiology. 289 (2): 517–534. doi:10.1148/radiol.2018181151. ISSN 0033-8419. PMC 6209069. PMID 30204075.
- Grobner, T. (2005). "Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?". Nephrology Dialysis Transplantation. 21 (4): 1104–1108. doi:10.1093/ndt/gfk062. PMID 16431890.
- Marckmann, P.; Skov, L.; Rossen, K.; Dupont, A.; Damholt, M.B.; Heaf, J.G.; Thomsen, H.S. (2006). "Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging". Journal of the American Society of Nephrology. 17 (9): 2359–2362. doi:10.1681/ASN.2006060601. PMID 16885403.
- Thomsen, H.S.; Morcos, S.K.; Dawson, P. (2006). "Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?". Clinical Radiology. 61 (11): 905–906. doi:10.1016/j.crad.2006.09.003. PMID 17018301.
- Kanal, E.; Barkovich, A.J.; Bell, C.; Borgstede, J.P.; Bradley, W.G.; Froelich, J.W.; et al. (ACR Blue Ribbon Panel on MR Safety) (2007). "ACR Guidance Document for Safe MR Practices: 2007". American Journal of Roentgenology. 188 (6): 1447–1474. doi:10.2214/AJR.06.1616. PMID 17515363.
- Lim, Yu Jeong; Bang, Jisun; Ko, Youngsun; Seo, Hyun Min; Jung, Woon Yong; Yi, Joo Hark; Han, Sang Woong; Yu, Mi Yeon (7 September 2020). "Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report". Journal of Korean Medical Science. 35 (35): e293. doi:10.3346/jkms.2020.35.e293. ISSN 1598-6357. PMC 7476800. PMID 32893521.
- Elmholdt, Tina Rask; Jørgensen, Bettina; Ramsing, Mette; Pedersen, Michael; Olesen, Anne Braae (June 2010). "Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol". NDT Plus. 3 (3): 285–287. doi:10.1093/ndtplus/sfq028. ISSN 1753-0784. PMC 5477958. PMID 28657062.
- Boehm IB (2022). "Gadolinium deposition disease (GDD): Does the missing link exist? – A suggested pathologic model". European Journal of Internal Medicine. 105 (11): 118–120. doi:10.1016/j.ejim.2022.07.008. PMID 35864076. S2CID 250648810.
- Bousquet, JC; et al. (March 1988). "Gd-DOTA: characterization of a new paramagnetic complex". Radiology. 166 (3): 693–8. doi:10.1148/radiology.166.3.3340763. PMID 3340763.
- Penfield, Jeffrey G.; Reilly, Robert F. (2007). "What nephrologists need to know about gadolinium". Nature Clinical Practice Nephrology. 3 (12): 654–668. doi:10.1038/ncpneph0660. PMID 18033225. S2CID 22435496.
- Boehm IB (2022). "Classification of gadolinium-based contrast agents (GBCAs) – adverse reactions". Magnetic Resonance Imaging. 85 (1): 1–2. doi:10.1016/j.mri.2021.10.006. PMID 34662698. S2CID 239027228.
- Stanescu, A. Luana; Shaw, Dennis W.; Murata, Nozomu; Murata, Kiyoko; Rutledge, Joe C.; Maloney, Ezekiel; Maravilla, Kenneth R. (March 2020). "Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: Pathological confirmation". Pediatric Radiology. 50 (3): 388–396. doi:10.1007/s00247-019-04535-w. ISSN 1432-1998. PMID 31989188. S2CID 210913930.
- Bussi, Simona; Coppo, Alessandra; Celeste, Roberto; Fanizzi, Antonello; Fringuello Mingo, Alberto; Ferraris, Andrea; et al. (4 February 2020). "Macrocyclic MR contrast agents: Evaluation of multiple-organ gadolinium retention in healthy rats". Insights into Imaging. 11 (1): 11. doi:10.1186/s13244-019-0824-5. ISSN 1869-4101. PMC 7000570. PMID 32020385.
- Bower, Danielle V.; Richter, Johannes K.; von Tengg-Kobligk, Hendrik; Heverhagen, Johannes T.; Runge, Val M. (August 2019). "Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent". Investigative Radiology. 54 (8): 453–463. doi:10.1097/RLI.0000000000000567. ISSN 1536-0210. PMID 31265439. S2CID 164486744.
- Forslin, Y.; Martola, J.; Bergendal, Å.; Fredrikson, S.; Wiberg, M.K.; Granberg, T. (August 2019). "Gadolinium retention in the brain: An MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis". American Journal of Neuroradiology. 40 (8): 1265–1273. doi:10.3174/ajnr.A6112. ISSN 0195-6108. PMC 7048491. PMID 31248867.
- Patel, Mihilkumar; Atyani, Almohannad; Salameh, Jean-Paul; McInnes, Matthew (October 2020). "Safety of intrathecal administration of gadolinium-based contrast agents: A systematic review and meta-analysis". Radiology. 297 (1): 75–83. doi:10.1148/radiol.2020191373. ISSN 1527-1315. PMID 32720867. S2CID 220842011. Retrieved 20 August 2021.
- Provenzano, David Anthony; Pellis, Zachary; DeRiggi, Leonard (25 April 2019). "Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: A case report and a comprehensive evidence-based review". Regional Anesthesia and Pain Medicine. 44 (7): 721–729. doi:10.1136/rapm-2019-100422. ISSN 1532-8651. PMID 31023932. S2CID 133608033.
- Taoka, Toshiaki; Naganawa, Shinji (10 April 2018). "Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain". Magnetic Resonance in Medical Sciences. 17 (2): 111–119. doi:10.2463/mrms.rev.2017-0116. ISSN 1880-2206. PMC 5891336. PMID 29367513.
- Mervak, Benjamin M.; Altun, Ersan; McGinty, Katrina A.; Hyslop, W. Brian; Semelka, Richard C.; Burke, Lauren M. (2019). "MRI in pregnancy: Indications and practical considerations". Journal of Magnetic Resonance Imaging. 49 (3): 621–631. doi:10.1002/jmri.26317. ISSN 1053-1807. PMID 30701610. S2CID 73412175.
- Nakamura, Hiroshi; Ito, Naoki; Kotake, Fumio; Mizokami, Yuji; Matsuoka, Takeshi (2000). "Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma". Journal of Gastroenterology. 35 (11): 849–855. doi:10.1007/s005350070022. PMID 11085494. S2CID 1037632.
- Shahrouki, Puja; Felker, Ely R.; Raman, Steven S.; Jeong, Woo Kyoung; Lu, David S.; Finn, J. Paul (24 October 2021). "Steady-state ferumoxytol-enhanced MRI: Early observations in benign abdominal organ masses and clinical implications". Abdominal Radiology. 47 (1): 460–470. doi:10.1007/s00261-021-03271-w. ISSN 2366-004X. PMC 8776683. PMID 34689252.
- Wang, Yi-Xiang J. (2011). "Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application". Quantitative Imaging in Medicine and Surgery. 1 (1): 35–40. doi:10.3978/j.issn.2223-4292.2011.08.03. PMC 3496483. PMID 23256052.
- Taylor, Robert M.; Huber, Dale L.; Monson, Todd C.; Ali, Abdul-Mehdi S.; Bisoffi, Marco; Sillerud, Laurel O. (2011). "Multifunctional iron platinum stealth immunomicelles: Targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging". Journal of Nanoparticle Research. 13 (10): 4717–4729. Bibcode:2011JNR....13.4717T. doi:10.1007/s11051-011-0439-3. PMC 3223933. PMID 22121333.
- Lacerda, Sara; Ndiaye, Daouda; Tóth, Éva (2021). "Chapter 3. Manganese Complexes as Contrast Agents for Magnetic Resonance Imaging". Metal Ions in Bio-Imaging Techniques. Springer. pp. 71–99. doi:10.1515/9783110685701-009. S2CID 233682771.
- Harisinghani, Mukesh G.; Jhaveri, Kartik S.; Weissleder, Ralph; Schima, Wolfgang; Saini, Sanjay; Hahn, Peter F.; Mueller, Peter R. (2001). "MRI contrast agents for evaluating focal hepatic lesions". Clinical Radiology. 56 (9): 714–725. doi:10.1053/crad.2001.0764. PMID 11585393.
- Sudarshana, D.M.; Nair, G.; Dwyer, J.T.; Steele, S.U.; Suto, D.J.; Wu, T.; et al. (August 2019). "Manganese-enhanced MRI of the brain in healthy volunteers". American Journal of Neuroradiology. 40 (8): 1309–1316. doi:10.3174/ajnr.A6152. PMC 6754109. PMID 31371354.
- Suto, D.J.; Nair, G.; Sudarshana, D.M.; Steel, S.U.; Dwyer, J.; Beck, E.S; et al. (August 2020). "Manganese-enhanced MRI in patients with multiple sclerosis". American Journal of Neuroradiology. 41 (9): 1569–1576. doi:10.3174/ajnr.A6665. PMC 7583091. PMID 32763897.
- Koretsky, Alan P.; Silva, Afonso C. (2004). "Manganese-enhanced magnetic resonance imaging (MEMRI)". NMR in Biomedicine. 17 (8): 527–531. doi:10.1002/nbm.940. PMID 15617051.
- Lin, Yi-Jen; Koretsky, Alan P. (1997). "Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function". Magnetic Resonance in Medicine. 38 (3): 378–388. doi:10.1002/mrm.1910380305. PMID 9339438. S2CID 25703430.
- Zhen, Zipeng; Xie, J. (2012). "Development of Manganese-Based Nanoparticles as Contrast Probes for Magnetic Resonance Imaging". Theranostics. 2 (1): 45–54. doi:10.7150/thno.3448. PMC 3263515. PMID 22272218.
- Bisset, G.S.; Emery, K.H.; Meza, M.P.; Rollins, N.K.; Don, S.; Shorr, J.S. (1996). "Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population". Pediatric Radiology. 26 (6): 409–415. doi:10.1007/BF01387316. PMID 8657479. S2CID 10032242.
- Xue, Shenghui; Qiao, Jingjuan; Pu, Fan; Cameron, Mathew; Yang, Jenny J. (2013). "Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers". Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 5 (2): 163–179. doi:10.1002/wnan.1205. PMC 4011496. PMID 23335551.
- Li, Shunyi; Jiang, Jie; Zou, Jin; Qiao, Jingjuan; Xue, Shenghui; Wei, Lixia; et al. (2012). "PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities". Journal of Inorganic Biochemistry. 107 (1): 111–118. doi:10.1016/j.jinorgbio.2011.11.004. PMC 3273044. PMID 22178673.
- Xue, Shenghui; Qiao, Jingjuan; Hubbard, Kendra; White, Natalie; Wei, Lixia; Li, Shunyi; et al. (2014). "Design of ProCAs (protein-based Gd3+ MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers". Medicinal Research Reviews. 34 (5): 1070–1099. doi:10.1002/med.21313. PMID 24615853. S2CID 42641594.
- Qiao, Jingjuan; Xue, Shenghui; Pu, Fan; White, Natalie; Liu, Zhi-Ren; Yang, Jenny J. (2014). "Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents". Journal of Biological Inorganic Chemistry. 19 (2): 259–270. doi:10.1007/s00775-013-1076-3. PMC 3931309. PMID 24366655.
europa.eu
ema.europa.eu
- EMA recommendations on gadolinium-containing contrast agents. ema.europa.eu (Report). European Medicines Agency. Retrieved 12 July 2018.
- "EMAs final opinion confirms restrictions on the use of linear gadolinium agents". ema.europa.eu (Press release). European Medicines Agency. 17 September 2018.
- https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents#overview
fda.gov
fda.gov
- Balzer, T. (2017). "Presence of gadolinium (Gd) in the brain and body". Bayer presentation to the September 8, 2017 meeting of the Medical Imaging Drugs Advisory Committee (PDF) (Report). Silver Spring, MD: Bayer HealthCare Pharmaceuticals Inc. Retrieved 1 April 2022 – via US FDA.
- Information on gadolinium-containing contrast agents (Report). Post-market Drug Safety Information for Patients and Providers. Retrieved 12 July 2018 – via fda.gov.
- FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI) (Report). FDA Drug Safety Communication. FDA. 18 June 2019.
- "FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings" (PDF). United States Food and Drug Administration. 19 December 2017.
This article incorporates text from this source, which is in the public domain. - "FDA warns gadolinium based contrast agents gbcas are retained body; requires new class warnings". US FDA. FDA Drug Safety Communication. 16 May 2018.
accessdata.fda.gov
- "NDA 020410 for GastroMark". FDA. Retrieved 12 February 2017.
guerbet.com
- Dr. Aashim Bhatia (presenter) (2019). Webinar on the role of the glymphatic system, and the growing awareness with gadolinium (Gd) deposits found in the brain (video). Archived from the original on 26 January 2023.
harvard.edu
ui.adsabs.harvard.edu
- Taylor, Robert M.; Huber, Dale L.; Monson, Todd C.; Ali, Abdul-Mehdi S.; Bisoffi, Marco; Sillerud, Laurel O. (2011). "Multifunctional iron platinum stealth immunomicelles: Targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging". Journal of Nanoparticle Research. 13 (10): 4717–4729. Bibcode:2011JNR....13.4717T. doi:10.1007/s11051-011-0439-3. PMC 3223933. PMID 22121333.
has-sante.fr
- Gadolinium pic RI reeval rapport annexe [Gadolinium peak RI re-eval report appendix]. has-sante.fr (Report) (in French). Retrieved 19 August 2021.
ismrm.org
- "Questions and Answers" (PDF). International Society for Magnetic Resonance in Medicine.
magnetic-resonance.org
- Rinck, Peter A. (2024). "Magnetic resonance contrast agents". Magnetic Resonance in Medicine. A critical introduction (14th ed.). TRTF – The Round Table Foundation / EMRF – European Magnetic Resonance Forum. "Magnetic resonance contrast agents". Magnetic Resonance in Medicine (www.magnetic-resonance.org) (e-Textbook).
mhra.gov.uk
- "Clariscan 0.5 mmol / ml solution for injection" (PDF). Summary of product characteristics. Oslo, NO: GE Healthcare AS. 22 February 2017. Archived from the original (PDF) on 1 March 2017. Retrieved 28 February 2017.
mr-tip.com
- "Magnetic resonance TIP – MRI database : Resovist". Mr-tip.com. Softways. Retrieved 20 June 2012.
nih.gov
pubmed.ncbi.nlm.nih.gov
- Geraldes, Carlos F.G.C.; Laurent, Sophie (2009). "Classification and basic properties of contrast agents for magnetic resonance imaging". Contrast Media & Molecular Imaging. 4 (1): 1–23. doi:10.1002/cmmi.265. PMID 19156706.
- Lentschig, M.G.; Reimer, P.; Rausch-Lentschig, U.L.; Allkemper, T.; Oelerich, M.; Laub, G. (1998). "Breath-hold gadolinium-enhanced MR angiography of the major vessels at 1.0 T: Dose-response findings and angiographic correlation". Radiology. 208 (2): 353–357. doi:10.1148/radiology.208.2.9680558. PMID 9680558.
- Lee MJ, Kim MJ, Yoon CS, Song SY, Park K, Kim WS (2011). "The T2-shortening effect of gadolinium and the optimal conditions for maximizing the CNR for evaluating the biliary system: a phantom study". Korean Journal of Radiology. 12 (3): 358–364. doi:10.3348/kjr.2011.12.3.358. PMC 3088853. PMID 21603295.
- Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK (November 2016). "MRI contrast agents: Classification and application (Review)". International Journal of Molecular Medicine. 38 (5): 1319–1326. doi:10.3892/ijmm.2016.2744. PMID 27666161.
- Bagnato F, Gauthier SA, Laule C, Moore G, Bove R, Cai Z, et al. (May 2020). "Imaging mechanisms of disease progression in multiple sclerosis: Beyond brain atrophy". Journal of Neuroimaging. 30 (3): 251–266. doi:10.1111/jon.12700. PMID 32418324. S2CID 218677556.
- Kanal, Emanuel (December 2016). "Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience". Magnetic Resonance Imaging. 34 (10): 1341–1345. doi:10.1016/j.mri.2016.08.017. ISSN 1873-5894. PMID 27608608.
- McDonald, Robert J.; Levine, Deborah; Weinreb, Jeffrey; Kanal, Emanuel; Davenport, Matthew S.; Ellis, James H.; Jacobs, Paula M.; Lenkinski, Robert E.; Maravilla, Kenneth R.; Prince, Martin R.; Rowley, Howard A. (November 2018). "Gadolinium retention: A research roadmap from the 2018 NIH / ACR / RSNA workshop on gadolinium chelates". Radiology. 289 (2): 517–534. doi:10.1148/radiol.2018181151. ISSN 0033-8419. PMC 6209069. PMID 30204075.
- Grobner, T. (2005). "Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?". Nephrology Dialysis Transplantation. 21 (4): 1104–1108. doi:10.1093/ndt/gfk062. PMID 16431890.
- Marckmann, P.; Skov, L.; Rossen, K.; Dupont, A.; Damholt, M.B.; Heaf, J.G.; Thomsen, H.S. (2006). "Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging". Journal of the American Society of Nephrology. 17 (9): 2359–2362. doi:10.1681/ASN.2006060601. PMID 16885403.
- Centers for Disease Control and Prevention (CDC) (2007). "Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents". Morbidity and Mortality Weekly Report (MMWR). 56 (7). Centers for Disease Control and Prevention (CDC): 137–141. PMID 17318112.
- Thomsen, H.S.; Morcos, S.K.; Dawson, P. (2006). "Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?". Clinical Radiology. 61 (11): 905–906. doi:10.1016/j.crad.2006.09.003. PMID 17018301.
- Kanal, E.; Barkovich, A.J.; Bell, C.; Borgstede, J.P.; Bradley, W.G.; Froelich, J.W.; et al. (ACR Blue Ribbon Panel on MR Safety) (2007). "ACR Guidance Document for Safe MR Practices: 2007". American Journal of Roentgenology. 188 (6): 1447–1474. doi:10.2214/AJR.06.1616. PMID 17515363.
- Lim, Yu Jeong; Bang, Jisun; Ko, Youngsun; Seo, Hyun Min; Jung, Woon Yong; Yi, Joo Hark; Han, Sang Woong; Yu, Mi Yeon (7 September 2020). "Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report". Journal of Korean Medical Science. 35 (35): e293. doi:10.3346/jkms.2020.35.e293. ISSN 1598-6357. PMC 7476800. PMID 32893521.
- Elmholdt, Tina Rask; Jørgensen, Bettina; Ramsing, Mette; Pedersen, Michael; Olesen, Anne Braae (June 2010). "Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol". NDT Plus. 3 (3): 285–287. doi:10.1093/ndtplus/sfq028. ISSN 1753-0784. PMC 5477958. PMID 28657062.
- Boehm IB (2022). "Gadolinium deposition disease (GDD): Does the missing link exist? – A suggested pathologic model". European Journal of Internal Medicine. 105 (11): 118–120. doi:10.1016/j.ejim.2022.07.008. PMID 35864076. S2CID 250648810.
- Bousquet, JC; et al. (March 1988). "Gd-DOTA: characterization of a new paramagnetic complex". Radiology. 166 (3): 693–8. doi:10.1148/radiology.166.3.3340763. PMID 3340763.
- Penfield, Jeffrey G.; Reilly, Robert F. (2007). "What nephrologists need to know about gadolinium". Nature Clinical Practice Nephrology. 3 (12): 654–668. doi:10.1038/ncpneph0660. PMID 18033225. S2CID 22435496.
- Boehm IB (2022). "Classification of gadolinium-based contrast agents (GBCAs) – adverse reactions". Magnetic Resonance Imaging. 85 (1): 1–2. doi:10.1016/j.mri.2021.10.006. PMID 34662698. S2CID 239027228.
- Stanescu, A. Luana; Shaw, Dennis W.; Murata, Nozomu; Murata, Kiyoko; Rutledge, Joe C.; Maloney, Ezekiel; Maravilla, Kenneth R. (March 2020). "Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: Pathological confirmation". Pediatric Radiology. 50 (3): 388–396. doi:10.1007/s00247-019-04535-w. ISSN 1432-1998. PMID 31989188. S2CID 210913930.
- Bussi, Simona; Coppo, Alessandra; Celeste, Roberto; Fanizzi, Antonello; Fringuello Mingo, Alberto; Ferraris, Andrea; et al. (4 February 2020). "Macrocyclic MR contrast agents: Evaluation of multiple-organ gadolinium retention in healthy rats". Insights into Imaging. 11 (1): 11. doi:10.1186/s13244-019-0824-5. ISSN 1869-4101. PMC 7000570. PMID 32020385.
- Bower, Danielle V.; Richter, Johannes K.; von Tengg-Kobligk, Hendrik; Heverhagen, Johannes T.; Runge, Val M. (August 2019). "Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent". Investigative Radiology. 54 (8): 453–463. doi:10.1097/RLI.0000000000000567. ISSN 1536-0210. PMID 31265439. S2CID 164486744.
- Forslin, Y.; Martola, J.; Bergendal, Å.; Fredrikson, S.; Wiberg, M.K.; Granberg, T. (August 2019). "Gadolinium retention in the brain: An MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis". American Journal of Neuroradiology. 40 (8): 1265–1273. doi:10.3174/ajnr.A6112. ISSN 0195-6108. PMC 7048491. PMID 31248867.
- Patel, Mihilkumar; Atyani, Almohannad; Salameh, Jean-Paul; McInnes, Matthew (October 2020). "Safety of intrathecal administration of gadolinium-based contrast agents: A systematic review and meta-analysis". Radiology. 297 (1): 75–83. doi:10.1148/radiol.2020191373. ISSN 1527-1315. PMID 32720867. S2CID 220842011. Retrieved 20 August 2021.
- Provenzano, David Anthony; Pellis, Zachary; DeRiggi, Leonard (25 April 2019). "Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: A case report and a comprehensive evidence-based review". Regional Anesthesia and Pain Medicine. 44 (7): 721–729. doi:10.1136/rapm-2019-100422. ISSN 1532-8651. PMID 31023932. S2CID 133608033.
- Taoka, Toshiaki; Naganawa, Shinji (10 April 2018). "Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain". Magnetic Resonance in Medical Sciences. 17 (2): 111–119. doi:10.2463/mrms.rev.2017-0116. ISSN 1880-2206. PMC 5891336. PMID 29367513.
- Mervak, Benjamin M.; Altun, Ersan; McGinty, Katrina A.; Hyslop, W. Brian; Semelka, Richard C.; Burke, Lauren M. (2019). "MRI in pregnancy: Indications and practical considerations". Journal of Magnetic Resonance Imaging. 49 (3): 621–631. doi:10.1002/jmri.26317. ISSN 1053-1807. PMID 30701610. S2CID 73412175.
- Nakamura, Hiroshi; Ito, Naoki; Kotake, Fumio; Mizokami, Yuji; Matsuoka, Takeshi (2000). "Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma". Journal of Gastroenterology. 35 (11): 849–855. doi:10.1007/s005350070022. PMID 11085494. S2CID 1037632.
- Shahrouki, Puja; Felker, Ely R.; Raman, Steven S.; Jeong, Woo Kyoung; Lu, David S.; Finn, J. Paul (24 October 2021). "Steady-state ferumoxytol-enhanced MRI: Early observations in benign abdominal organ masses and clinical implications". Abdominal Radiology. 47 (1): 460–470. doi:10.1007/s00261-021-03271-w. ISSN 2366-004X. PMC 8776683. PMID 34689252.
- Wang, Yi-Xiang J. (2011). "Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application". Quantitative Imaging in Medicine and Surgery. 1 (1): 35–40. doi:10.3978/j.issn.2223-4292.2011.08.03. PMC 3496483. PMID 23256052.
- Taylor, Robert M.; Huber, Dale L.; Monson, Todd C.; Ali, Abdul-Mehdi S.; Bisoffi, Marco; Sillerud, Laurel O. (2011). "Multifunctional iron platinum stealth immunomicelles: Targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging". Journal of Nanoparticle Research. 13 (10): 4717–4729. Bibcode:2011JNR....13.4717T. doi:10.1007/s11051-011-0439-3. PMC 3223933. PMID 22121333.
- Harisinghani, Mukesh G.; Jhaveri, Kartik S.; Weissleder, Ralph; Schima, Wolfgang; Saini, Sanjay; Hahn, Peter F.; Mueller, Peter R. (2001). "MRI contrast agents for evaluating focal hepatic lesions". Clinical Radiology. 56 (9): 714–725. doi:10.1053/crad.2001.0764. PMID 11585393.
- Sudarshana, D.M.; Nair, G.; Dwyer, J.T.; Steele, S.U.; Suto, D.J.; Wu, T.; et al. (August 2019). "Manganese-enhanced MRI of the brain in healthy volunteers". American Journal of Neuroradiology. 40 (8): 1309–1316. doi:10.3174/ajnr.A6152. PMC 6754109. PMID 31371354.
- Suto, D.J.; Nair, G.; Sudarshana, D.M.; Steel, S.U.; Dwyer, J.; Beck, E.S; et al. (August 2020). "Manganese-enhanced MRI in patients with multiple sclerosis". American Journal of Neuroradiology. 41 (9): 1569–1576. doi:10.3174/ajnr.A6665. PMC 7583091. PMID 32763897.
- Koretsky, Alan P.; Silva, Afonso C. (2004). "Manganese-enhanced magnetic resonance imaging (MEMRI)". NMR in Biomedicine. 17 (8): 527–531. doi:10.1002/nbm.940. PMID 15617051.
- Lin, Yi-Jen; Koretsky, Alan P. (1997). "Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function". Magnetic Resonance in Medicine. 38 (3): 378–388. doi:10.1002/mrm.1910380305. PMID 9339438. S2CID 25703430.
- Zhen, Zipeng; Xie, J. (2012). "Development of Manganese-Based Nanoparticles as Contrast Probes for Magnetic Resonance Imaging". Theranostics. 2 (1): 45–54. doi:10.7150/thno.3448. PMC 3263515. PMID 22272218.
- Bisset, G.S.; Emery, K.H.; Meza, M.P.; Rollins, N.K.; Don, S.; Shorr, J.S. (1996). "Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population". Pediatric Radiology. 26 (6): 409–415. doi:10.1007/BF01387316. PMID 8657479. S2CID 10032242.
- Xue, Shenghui; Qiao, Jingjuan; Pu, Fan; Cameron, Mathew; Yang, Jenny J. (2013). "Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers". Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 5 (2): 163–179. doi:10.1002/wnan.1205. PMC 4011496. PMID 23335551.
- Li, Shunyi; Jiang, Jie; Zou, Jin; Qiao, Jingjuan; Xue, Shenghui; Wei, Lixia; et al. (2012). "PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities". Journal of Inorganic Biochemistry. 107 (1): 111–118. doi:10.1016/j.jinorgbio.2011.11.004. PMC 3273044. PMID 22178673.
- Xue, Shenghui; Qiao, Jingjuan; Hubbard, Kendra; White, Natalie; Wei, Lixia; Li, Shunyi; et al. (2014). "Design of ProCAs (protein-based Gd3+ MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers". Medicinal Research Reviews. 34 (5): 1070–1099. doi:10.1002/med.21313. PMID 24615853. S2CID 42641594.
- Qiao, Jingjuan; Xue, Shenghui; Pu, Fan; White, Natalie; Liu, Zhi-Ren; Yang, Jenny J. (2014). "Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents". Journal of Biological Inorganic Chemistry. 19 (2): 259–270. doi:10.1007/s00775-013-1076-3. PMC 3931309. PMID 24366655.
ncbi.nlm.nih.gov
- Lee MJ, Kim MJ, Yoon CS, Song SY, Park K, Kim WS (2011). "The T2-shortening effect of gadolinium and the optimal conditions for maximizing the CNR for evaluating the biliary system: a phantom study". Korean Journal of Radiology. 12 (3): 358–364. doi:10.3348/kjr.2011.12.3.358. PMC 3088853. PMID 21603295.
- McDonald, Robert J.; Levine, Deborah; Weinreb, Jeffrey; Kanal, Emanuel; Davenport, Matthew S.; Ellis, James H.; Jacobs, Paula M.; Lenkinski, Robert E.; Maravilla, Kenneth R.; Prince, Martin R.; Rowley, Howard A. (November 2018). "Gadolinium retention: A research roadmap from the 2018 NIH / ACR / RSNA workshop on gadolinium chelates". Radiology. 289 (2): 517–534. doi:10.1148/radiol.2018181151. ISSN 0033-8419. PMC 6209069. PMID 30204075.
- Lim, Yu Jeong; Bang, Jisun; Ko, Youngsun; Seo, Hyun Min; Jung, Woon Yong; Yi, Joo Hark; Han, Sang Woong; Yu, Mi Yeon (7 September 2020). "Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report". Journal of Korean Medical Science. 35 (35): e293. doi:10.3346/jkms.2020.35.e293. ISSN 1598-6357. PMC 7476800. PMID 32893521.
- Elmholdt, Tina Rask; Jørgensen, Bettina; Ramsing, Mette; Pedersen, Michael; Olesen, Anne Braae (June 2010). "Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol". NDT Plus. 3 (3): 285–287. doi:10.1093/ndtplus/sfq028. ISSN 1753-0784. PMC 5477958. PMID 28657062.
- Bussi, Simona; Coppo, Alessandra; Celeste, Roberto; Fanizzi, Antonello; Fringuello Mingo, Alberto; Ferraris, Andrea; et al. (4 February 2020). "Macrocyclic MR contrast agents: Evaluation of multiple-organ gadolinium retention in healthy rats". Insights into Imaging. 11 (1): 11. doi:10.1186/s13244-019-0824-5. ISSN 1869-4101. PMC 7000570. PMID 32020385.
- Forslin, Y.; Martola, J.; Bergendal, Å.; Fredrikson, S.; Wiberg, M.K.; Granberg, T. (August 2019). "Gadolinium retention in the brain: An MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis". American Journal of Neuroradiology. 40 (8): 1265–1273. doi:10.3174/ajnr.A6112. ISSN 0195-6108. PMC 7048491. PMID 31248867.
- Taoka, Toshiaki; Naganawa, Shinji (10 April 2018). "Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain". Magnetic Resonance in Medical Sciences. 17 (2): 111–119. doi:10.2463/mrms.rev.2017-0116. ISSN 1880-2206. PMC 5891336. PMID 29367513.
- Shahrouki, Puja; Felker, Ely R.; Raman, Steven S.; Jeong, Woo Kyoung; Lu, David S.; Finn, J. Paul (24 October 2021). "Steady-state ferumoxytol-enhanced MRI: Early observations in benign abdominal organ masses and clinical implications". Abdominal Radiology. 47 (1): 460–470. doi:10.1007/s00261-021-03271-w. ISSN 2366-004X. PMC 8776683. PMID 34689252.
- Wang, Yi-Xiang J. (2011). "Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application". Quantitative Imaging in Medicine and Surgery. 1 (1): 35–40. doi:10.3978/j.issn.2223-4292.2011.08.03. PMC 3496483. PMID 23256052.
- Taylor, Robert M.; Huber, Dale L.; Monson, Todd C.; Ali, Abdul-Mehdi S.; Bisoffi, Marco; Sillerud, Laurel O. (2011). "Multifunctional iron platinum stealth immunomicelles: Targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging". Journal of Nanoparticle Research. 13 (10): 4717–4729. Bibcode:2011JNR....13.4717T. doi:10.1007/s11051-011-0439-3. PMC 3223933. PMID 22121333.
- Sudarshana, D.M.; Nair, G.; Dwyer, J.T.; Steele, S.U.; Suto, D.J.; Wu, T.; et al. (August 2019). "Manganese-enhanced MRI of the brain in healthy volunteers". American Journal of Neuroradiology. 40 (8): 1309–1316. doi:10.3174/ajnr.A6152. PMC 6754109. PMID 31371354.
- Suto, D.J.; Nair, G.; Sudarshana, D.M.; Steel, S.U.; Dwyer, J.; Beck, E.S; et al. (August 2020). "Manganese-enhanced MRI in patients with multiple sclerosis". American Journal of Neuroradiology. 41 (9): 1569–1576. doi:10.3174/ajnr.A6665. PMC 7583091. PMID 32763897.
- Zhen, Zipeng; Xie, J. (2012). "Development of Manganese-Based Nanoparticles as Contrast Probes for Magnetic Resonance Imaging". Theranostics. 2 (1): 45–54. doi:10.7150/thno.3448. PMC 3263515. PMID 22272218.
- Xue, Shenghui; Qiao, Jingjuan; Pu, Fan; Cameron, Mathew; Yang, Jenny J. (2013). "Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers". Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 5 (2): 163–179. doi:10.1002/wnan.1205. PMC 4011496. PMID 23335551.
- Li, Shunyi; Jiang, Jie; Zou, Jin; Qiao, Jingjuan; Xue, Shenghui; Wei, Lixia; et al. (2012). "PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities". Journal of Inorganic Biochemistry. 107 (1): 111–118. doi:10.1016/j.jinorgbio.2011.11.004. PMC 3273044. PMID 22178673.
- Qiao, Jingjuan; Xue, Shenghui; Pu, Fan; White, Natalie; Liu, Zhi-Ren; Yang, Jenny J. (2014). "Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents". Journal of Biological Inorganic Chemistry. 19 (2): 259–270. doi:10.1007/s00775-013-1076-3. PMC 3931309. PMID 24366655.
dailymed.nlm.nih.gov
- "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
sec.gov
semanticscholar.org
api.semanticscholar.org
- Tircsó, Gyulia; Molńar, Enricő; Csupász, Tibor; Garda, Zoltan; Botár, Richárd; Kálmán, Ferenc K.; Kovács, Zoltan; Brücher, Ernő; Tóth, Imre (2021). "Chapter 2. Gadolinium(III)-based contrast agents for magnetic resonance imaging: A re-appraisal". Metal Ions in Bio-Imaging Techniques. Springer. pp. 39–70. doi:10.1515/9783110685701-008. S2CID 233702931.
- McLeod, Shauanna M.; Mead, Thomas J. (2021). "Chapter 12. Magnetic resonance theranostics: An overview of gadolinium(II)-based strategies and magnetic particle imaging". Metal Ions in Bio-Imaging Techniques. Springer. pp. 347–370. doi:10.1515/9783110685701-018. S2CID 233710460.
- Bagnato F, Gauthier SA, Laule C, Moore G, Bove R, Cai Z, et al. (May 2020). "Imaging mechanisms of disease progression in multiple sclerosis: Beyond brain atrophy". Journal of Neuroimaging. 30 (3): 251–266. doi:10.1111/jon.12700. PMID 32418324. S2CID 218677556.
- Boehm IB (2022). "Gadolinium deposition disease (GDD): Does the missing link exist? – A suggested pathologic model". European Journal of Internal Medicine. 105 (11): 118–120. doi:10.1016/j.ejim.2022.07.008. PMID 35864076. S2CID 250648810.
- Penfield, Jeffrey G.; Reilly, Robert F. (2007). "What nephrologists need to know about gadolinium". Nature Clinical Practice Nephrology. 3 (12): 654–668. doi:10.1038/ncpneph0660. PMID 18033225. S2CID 22435496.
- Boehm IB (2022). "Classification of gadolinium-based contrast agents (GBCAs) – adverse reactions". Magnetic Resonance Imaging. 85 (1): 1–2. doi:10.1016/j.mri.2021.10.006. PMID 34662698. S2CID 239027228.
- Stanescu, A. Luana; Shaw, Dennis W.; Murata, Nozomu; Murata, Kiyoko; Rutledge, Joe C.; Maloney, Ezekiel; Maravilla, Kenneth R. (March 2020). "Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: Pathological confirmation". Pediatric Radiology. 50 (3): 388–396. doi:10.1007/s00247-019-04535-w. ISSN 1432-1998. PMID 31989188. S2CID 210913930.
- Bower, Danielle V.; Richter, Johannes K.; von Tengg-Kobligk, Hendrik; Heverhagen, Johannes T.; Runge, Val M. (August 2019). "Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent". Investigative Radiology. 54 (8): 453–463. doi:10.1097/RLI.0000000000000567. ISSN 1536-0210. PMID 31265439. S2CID 164486744.
- Patel, Mihilkumar; Atyani, Almohannad; Salameh, Jean-Paul; McInnes, Matthew (October 2020). "Safety of intrathecal administration of gadolinium-based contrast agents: A systematic review and meta-analysis". Radiology. 297 (1): 75–83. doi:10.1148/radiol.2020191373. ISSN 1527-1315. PMID 32720867. S2CID 220842011. Retrieved 20 August 2021.
- Provenzano, David Anthony; Pellis, Zachary; DeRiggi, Leonard (25 April 2019). "Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: A case report and a comprehensive evidence-based review". Regional Anesthesia and Pain Medicine. 44 (7): 721–729. doi:10.1136/rapm-2019-100422. ISSN 1532-8651. PMID 31023932. S2CID 133608033.
- Mervak, Benjamin M.; Altun, Ersan; McGinty, Katrina A.; Hyslop, W. Brian; Semelka, Richard C.; Burke, Lauren M. (2019). "MRI in pregnancy: Indications and practical considerations". Journal of Magnetic Resonance Imaging. 49 (3): 621–631. doi:10.1002/jmri.26317. ISSN 1053-1807. PMID 30701610. S2CID 73412175.
- Nakamura, Hiroshi; Ito, Naoki; Kotake, Fumio; Mizokami, Yuji; Matsuoka, Takeshi (2000). "Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma". Journal of Gastroenterology. 35 (11): 849–855. doi:10.1007/s005350070022. PMID 11085494. S2CID 1037632.
- Lacerda, Sara; Ndiaye, Daouda; Tóth, Éva (2021). "Chapter 3. Manganese Complexes as Contrast Agents for Magnetic Resonance Imaging". Metal Ions in Bio-Imaging Techniques. Springer. pp. 71–99. doi:10.1515/9783110685701-009. S2CID 233682771.
- Lin, Yi-Jen; Koretsky, Alan P. (1997). "Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function". Magnetic Resonance in Medicine. 38 (3): 378–388. doi:10.1002/mrm.1910380305. PMID 9339438. S2CID 25703430.
- Bisset, G.S.; Emery, K.H.; Meza, M.P.; Rollins, N.K.; Don, S.; Shorr, J.S. (1996). "Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population". Pediatric Radiology. 26 (6): 409–415. doi:10.1007/BF01387316. PMID 8657479. S2CID 10032242.
- Xue, Shenghui; Qiao, Jingjuan; Hubbard, Kendra; White, Natalie; Wei, Lixia; Li, Shunyi; et al. (2014). "Design of ProCAs (protein-based Gd3+ MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers". Medicinal Research Reviews. 34 (5): 1070–1099. doi:10.1002/med.21313. PMID 24615853. S2CID 42641594.
thefreelibrary.com
- "Update on Sinerem (TM) in Europe". AMAG Pharmaceuticals. 13 December 2007. Archived from the original on 23 March 2019. Retrieved 20 June 2012 – via Thefreelibrary.com.
unibe.ch
boris.unibe.ch
- Boehm IB (2022). "Classification of gadolinium-based contrast agents (GBCAs) – adverse reactions". Magnetic Resonance Imaging. 85 (1): 1–2. doi:10.1016/j.mri.2021.10.006. PMID 34662698. S2CID 239027228.
web.archive.org
- "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
- Dr. Aashim Bhatia (presenter) (2019). Webinar on the role of the glymphatic system, and the growing awareness with gadolinium (Gd) deposits found in the brain (video). Archived from the original on 26 January 2023.
- "Feridex". Amagpharma.com. Archived from the original on 15 June 2012. Retrieved 20 June 2012.
- "Update on Sinerem (TM) in Europe". AMAG Pharmaceuticals. 13 December 2007. Archived from the original on 23 March 2019. Retrieved 20 June 2012 – via Thefreelibrary.com.
- "Newly approved drug therapies (105) GastroMARK (Advanced Magnetics)". CenterWatch. Archived from the original on 29 December 2011. Retrieved 20 June 2012.
- "Clariscan 0.5 mmol / ml solution for injection" (PDF). Summary of product characteristics. Oslo, NO: GE Healthcare AS. 22 February 2017. Archived from the original (PDF) on 1 March 2017. Retrieved 28 February 2017.
who.int
- Pharmaceuticals: Restrictions in use and availability (PDF) (Report). World Health Organization. 2010. p. 14 – via who.int.
worldcat.org
search.worldcat.org
- Kanal, Emanuel (December 2016). "Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience". Magnetic Resonance Imaging. 34 (10): 1341–1345. doi:10.1016/j.mri.2016.08.017. ISSN 1873-5894. PMID 27608608.
- McDonald, Robert J.; Levine, Deborah; Weinreb, Jeffrey; Kanal, Emanuel; Davenport, Matthew S.; Ellis, James H.; Jacobs, Paula M.; Lenkinski, Robert E.; Maravilla, Kenneth R.; Prince, Martin R.; Rowley, Howard A. (November 2018). "Gadolinium retention: A research roadmap from the 2018 NIH / ACR / RSNA workshop on gadolinium chelates". Radiology. 289 (2): 517–534. doi:10.1148/radiol.2018181151. ISSN 0033-8419. PMC 6209069. PMID 30204075.
- Lim, Yu Jeong; Bang, Jisun; Ko, Youngsun; Seo, Hyun Min; Jung, Woon Yong; Yi, Joo Hark; Han, Sang Woong; Yu, Mi Yeon (7 September 2020). "Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report". Journal of Korean Medical Science. 35 (35): e293. doi:10.3346/jkms.2020.35.e293. ISSN 1598-6357. PMC 7476800. PMID 32893521.
- Elmholdt, Tina Rask; Jørgensen, Bettina; Ramsing, Mette; Pedersen, Michael; Olesen, Anne Braae (June 2010). "Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol". NDT Plus. 3 (3): 285–287. doi:10.1093/ndtplus/sfq028. ISSN 1753-0784. PMC 5477958. PMID 28657062.
- Stanescu, A. Luana; Shaw, Dennis W.; Murata, Nozomu; Murata, Kiyoko; Rutledge, Joe C.; Maloney, Ezekiel; Maravilla, Kenneth R. (March 2020). "Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: Pathological confirmation". Pediatric Radiology. 50 (3): 388–396. doi:10.1007/s00247-019-04535-w. ISSN 1432-1998. PMID 31989188. S2CID 210913930.
- Bussi, Simona; Coppo, Alessandra; Celeste, Roberto; Fanizzi, Antonello; Fringuello Mingo, Alberto; Ferraris, Andrea; et al. (4 February 2020). "Macrocyclic MR contrast agents: Evaluation of multiple-organ gadolinium retention in healthy rats". Insights into Imaging. 11 (1): 11. doi:10.1186/s13244-019-0824-5. ISSN 1869-4101. PMC 7000570. PMID 32020385.
- Bower, Danielle V.; Richter, Johannes K.; von Tengg-Kobligk, Hendrik; Heverhagen, Johannes T.; Runge, Val M. (August 2019). "Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent". Investigative Radiology. 54 (8): 453–463. doi:10.1097/RLI.0000000000000567. ISSN 1536-0210. PMID 31265439. S2CID 164486744.
- Forslin, Y.; Martola, J.; Bergendal, Å.; Fredrikson, S.; Wiberg, M.K.; Granberg, T. (August 2019). "Gadolinium retention in the brain: An MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis". American Journal of Neuroradiology. 40 (8): 1265–1273. doi:10.3174/ajnr.A6112. ISSN 0195-6108. PMC 7048491. PMID 31248867.
- Patel, Mihilkumar; Atyani, Almohannad; Salameh, Jean-Paul; McInnes, Matthew (October 2020). "Safety of intrathecal administration of gadolinium-based contrast agents: A systematic review and meta-analysis". Radiology. 297 (1): 75–83. doi:10.1148/radiol.2020191373. ISSN 1527-1315. PMID 32720867. S2CID 220842011. Retrieved 20 August 2021.
- Provenzano, David Anthony; Pellis, Zachary; DeRiggi, Leonard (25 April 2019). "Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: A case report and a comprehensive evidence-based review". Regional Anesthesia and Pain Medicine. 44 (7): 721–729. doi:10.1136/rapm-2019-100422. ISSN 1532-8651. PMID 31023932. S2CID 133608033.
- Taoka, Toshiaki; Naganawa, Shinji (10 April 2018). "Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain". Magnetic Resonance in Medical Sciences. 17 (2): 111–119. doi:10.2463/mrms.rev.2017-0116. ISSN 1880-2206. PMC 5891336. PMID 29367513.
- Mervak, Benjamin M.; Altun, Ersan; McGinty, Katrina A.; Hyslop, W. Brian; Semelka, Richard C.; Burke, Lauren M. (2019). "MRI in pregnancy: Indications and practical considerations". Journal of Magnetic Resonance Imaging. 49 (3): 621–631. doi:10.1002/jmri.26317. ISSN 1053-1807. PMID 30701610. S2CID 73412175.
- Shahrouki, Puja; Felker, Ely R.; Raman, Steven S.; Jeong, Woo Kyoung; Lu, David S.; Finn, J. Paul (24 October 2021). "Steady-state ferumoxytol-enhanced MRI: Early observations in benign abdominal organ masses and clinical implications". Abdominal Radiology. 47 (1): 460–470. doi:10.1007/s00261-021-03271-w. ISSN 2366-004X. PMC 8776683. PMID 34689252.